Ernexa Therapeutics (NASDAQ:ERNA) Now Covered by Analysts at Brookline Capital Markets

Brookline Capital Markets started coverage on shares of Ernexa Therapeutics (NASDAQ:ERNA) in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Stock Down 7.6%

Shares of NASDAQ:ERNA traded down $0.59 during midday trading on Thursday, reaching $7.23. 1,053,364 shares of the company traded hands, compared to its average volume of 912,316. Ernexa Therapeutics has a 12 month low of $3.18 and a 12 month high of $100.46. The firm’s fifty day moving average price is $5.89 and its two-hundred day moving average price is $21.13. The firm has a market capitalization of $8.45 million, a price-to-earnings ratio of -0.09 and a beta of 1.88.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Institutional investors own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.